Skip to content

Effects of oat consumption on metabolism and gut microbiome in individuals with metabolic syndrome – a human dietary intervention trial

Effects of oat consumption on metabolism and gut microbiome in individuals with metabolic syndrome – a human dietary intervention trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00022169
Enrollment
68
Registered
2020-07-28
Start date
2020-10-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E88.9

Interventions

Group 1: Intervention group study arm 1: Two-day low-calorie diet consisting of three protions of oat porridge a day (3 x 100 g oat flakes/day). The preparation of the porridge is done with water (max

Sponsors

Rheinische Friedrich-Wilhelms-Universität Bonn Institut für Ernährungs- und Lebensmittelwissenschaften/ Abteilung Ernährung und Mikrobiota
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: BMI 27-39,9 kg/m²; metabolic syndrome: visceral fat distribution, measured by waist circumference (?: = 80 cm; ?: = 94 cm) + two of the following risk factors: prehypertension (= 120-139 mmHg systolic and/ or = 80-89 mmHg diastolic) or hypertension state 1 (= 140-159 mmHg systolic and/ or = 90-99 mmHg diastolic), triglyceridemia (= 1,7 mmol/L), low HDL-cholesterol (?: 5,6 mmol/l); Non-smoker (for at least 3 months), written declaration of consent for participation in the study. The limit values for waist circumference, triglycerides and HDL cholesterol (all under fasting conditions) correspond to the parameters of metabolic syndrome according to the International Diabetes Federation (IDF). Blood pressure was based on the American classification.

Exclusion criteria

Exclusion criteria: Regular oat intake (at least 1 usual portion/week); Taking medications that affect glucose metabolism; diagnosed T2DM, chronic hepatic diseases (Transaminases > Twice the standard value), gastrointestinal diseases, chronic inflammatory diseases (hs-CRP > 30 mg/L), cardiovascular events, thyroid disease, tumour diseases, acute diseases or recent operations; Pregnancy, breastfeeding period; allergies and intolerances to oat products; antibiotic therapy 3 weeks before the start of the study; alcohol and drug abuse; regular intake of supplements (n-3 fatty acids, vitamin E, magnesium, calcium, iron); Planned lifestyle change; vegetarian or vegan diet; participation in another clinical trial simultaneously/in the last 30 days; sensory or motor problems that make it impossible to use the "neotiv" app; other exclusion criteria at the discretion of the doctor/investigator.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of (dihydro-)ferulic acid (measurement is carried out before the intervention (baseline), during and after the intervention phase. Blood is taken under fasting conditions.)

Secondary

MeasureTime frame
concentration of oat phenolics in blood, urine and fecal samples (Avenanthramides as compliance marker, untargeted analysis), intestinal microbiome (composition, diversity), concentration of various intestinal hormones (GLP-1, GLP-2, GIP, ghrelin), parameter of intestinal permeability (zonulin), parameter of glucose and lipid metabolism (glucose, insulin, HbA1c, lipids, lipoproteins, FFS), parameter of inflammation, neuroinflammation and antioxidative defence (IL-6, TNF-a, CRP, NFL, vitamin A, E, ß-carotene, vitamin C, oxLDL), SCFAs (serum, fecal), amino acids (tryptophan, tyrosine), serotonin, electrolytes (sodium, potassium, magnesium); Further parameters: anthropometrics (body weight, body height, waist and hip ratio, body composition (BodPod), resting energy expenditure (QuarkRMR), cognition + concentration and mental state (questionnaire, digital tests); Security parameters: Small blood count, Parameters of renal and hepatic function (GOT, GPT, GGT, bilirubin, uric acid, urea, creatinine).

Countries

Germany

Contacts

Public ContactLinda Jakobs

Rheinische Friedrich-Wilhelms-Universität Bonn Institut für Ernährungs- und Lebensmittelwissenschaften/ Abteilung Ernährung und Mikrobiota

ljakobs@uni-bonn.de0228 – 73 4303

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 25, 2026